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Abstract Alterations of gut microbes play a role in the
pathogenesis and progression of many disorders including
liver and gastrointestinal diseases. Both qualitative and
quantitative changes in gut microbiota have been associ-
ated with liver disease. Intestinal dysbiosis can disrupt the
integrity of the intestinal barrier leading to pathological
bacterial translocation and the initiation of an inflammatory
response in the liver. In order to sustain symbiosis and
protect from pathological bacterial translocation, antimi-
crobial proteins (AMPs) such as a-defensins and C-type
lectins are expressed in the gastrointestinal tract. In this
review, we provide an overview of the role of AMPs in
different chronic liver disease such as alcoholic steato-
hepatitis, non-alcoholic fatty liver disease, and cirrhosis. In
addition, potential approaches to modulate the function of
AMPs and prevent bacterial translocation are discussed.
Keywords Dysbiosis  Innate immune system  Bacterial
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Abbreviations
AhR Aryl hydrocarbon receptor
AMPs Antimicrobial proteins
FXR Farnesoid X receptor
IL-22 Interleukin 22
ILC3 Innate lymphoid cells type 3
LPS Lipopolysaccharide
NAFLD Non-alcoholic fatty liver disease
NASH Non-alcoholic steatohepatitis
Reg Regenerating island-derived protein
TLR Toll-like receptor
Introduction
The gastrointestinal tract is the largest surface area in the
body and is home to a vast consortium of symbiotic bacteria
that play an important role in human health and disease.
Microbiota are involved in basic human biological pro-
cesses, including food digestion, modulation of immune
responses, regulation of epithelial development and gener-
ation of a variety of products as a result of microbial meta-
bolic activities. These products together with host–bacteria
interactions influence both normal physiology and disease
susceptibility. A disruption of the symbiosis between
microbiota and host is known as dysbiosis and is described in
multiple chronic diseases such as obesity [1], malnutrition
[2], neurological disorders [3], inflammatory bowel disease
[4], diabetes mellitus [5], metabolic syndrome, atheroscle-
rosis [6], cancer [7] and liver disease [8–10].
Nutrition, other environmental and genetic factors can
independently cause changes in the gut microbiota com-
position, which can present as qualitative changes such as
increased proportions of harmful bacteria and reduced
levels of beneficial bacteria, and also quantitative changes
in the total amount of bacteria (intestinal bacterial over-
growth) [10, 11]. Intestinal bacterial overgrowth can affect
both the luminal compartment and mucosa-associated
bacteria [12]. As a result of dysbiosis, intestinal epithelial
integrity is lost, mucus-associated defense is weakened and
& Bernd Schnabl
beschnabl@ucsd.edu
1 Department of Medicine, University of California San Diego,
La Jolla, CA, USA
2 Department of Medicine, VA San Diego Healthcare System,
San Diego, CA, USA
123
J Gastroenterol (2019) 54:209–217
https://doi.org/10.1007/s00535-018-1521-8
the intestine becomes more permeable. Hence, viable
bacteria or microbial products are able to migrate from the
intestines to mesenteric lymph nodes or other extra-gas-
trointestinal organs via the bloodstream, causing disease
[13]. At distant sites, these bacterial products can be rec-
ognized via toll-like receptors (TLRs). Specific TLRs
recognize pathogen-associated molecular patterns associ-
ated with bacteria. TLR-2 may be activated by various
membrane components of Gram-positive bacteria. TLR-4
recognizes the lipid A portion of lipopolysaccharide (LPS).
TLR-5 may be activated by flagellin, and bacterial DNA
activates TLR-9. Activation of TLRs on macrophages leads
to a variety of inflammatory cascades that in turn cause
inflammation and may represent the driving force behind
disease progression [14]. In addition, upon liver injury,
hepatic stellate cells undergo an activation process in
which they express TLR4. Therefore, LPS and other TLR
ligands may enhance fibrogenic responses via direct stel-
late cell activation. Lastly, as also hepatocytes express
TLR-2 and TLR-4, bacterial recognition by TLRs on
hepatocytes may account for cell death occurring during
liver injury [15].
Besides the tightly interconnected intestinal epithelial
lining, the physical barrier to separate microbiota from
intestinal surface is formed by a mucus layer. This mucus
is secreted by goblet cells and largely consists of mucin
glycoprotein sheets. In the colon, where mucus consists of
two layers, the inner mucus layer is devoid of bacteria
whereas the outer is colonized [16]. Likewise, in the small
intestine bacteria are kept on distance from the epithelial
wall [17]. In order to sustain the mucosal barrier and pro-
tect the host against enteric pathogens, a range of host
antimicrobial factors are produced in the intestinal
epithelium [18]. These intestinal antimicrobial proteins
(AMPs) mediate killing of bacteria by attacking the basic
cell wall structures through enzymatic and non-enzymatic
mechanisms. Interestingly, dysfunctional antimicrobial
defense has been described in different chronic liver dis-
eases [19–21].
In this review, we summarize evidence supporting the
contribution of bacterial translocation and the role of
antimicrobial proteins in the development and progression
of different chronic liver diseases such as alcoholic and
non-alcoholic fatty liver disease (NAFLD), and cirrho-
sis (Fig. 1). Moreover, potential approaches to modulate
the function of antimicrobial proteins to prevent bacterial
translocation are discussed.
Antimicrobial proteins
The surface of the mammalian intestine continuously
encounters bacteria, fungi, viruses and parasites that could
act as pathogens. In order to cope with these microbial
challenges, a diverse collection of AMPs are produced in
the intestinal epithelium and Paneth cells which rapidly kill
or inactivate microorganisms. These AMPs consist of dif-
ferent protein families, which include defensins, catheli-
cidins, C-type lectins (such as the regenerating islet-
derived protein (REG) family), ribonucleases (RNases,
such as angiogenin 4) and S100 proteins (such as calpro-
tectin (also known as S100A8–S100A9) and psoriasin (also
known as S100A7)) [22]. Although most AMPs attack
bacterial cell wall components, different AMP families use
distinct molecular mechanisms to kill microorganisms [18].
This might explain that microbial resistance to multiple
AMPs is rare.
The expression, secretion and activity of AMPs are
under tight control of different factors. First, studies of
germ-free mice have revealed that some intestinal AMPs
require bacterial signals for their expression, whereas
others are expressed independently of the microbiota [18].
For example, the expression of regenerating island-derived
protein 3 gamma (REG3c) is essentially absent in germ-
free mice and is upregulated on colonization with a con-
ventional microbiota [23]. Besides bacterial signals, host
immune function controls the expression of these bacteri-
ally regulated AMPs. Studies in mice have shown that
bacterial recognition by TLRs on intestinal epithelial cells
is required for and upregulates the expression of REG3c
and REG3b [24, 25]. In addition, intestinal epithelial cell
expression of REG3c also requires interleukin 22 (IL-22), a
cytokine mainly expressed by RORct? type 3 innate
lymphoid cells (ILC3s) in the gut [26]. The production of
this cytokine by ILC3s is enhanced by activation of the aryl
hydrocarbon receptor (AhR) via specific bacterially
derived molecules [27–29], indicating that bacteria might
enhance the immune response to protect the host from
harmful pathogens. Taken together, the expression and
function of AMPs are the result of a symbiotic interplay
between host and commensals, in which interruptions
might cause disease. Here, we further describe the role of
AMPs, more specifically C-type lectins, in different
chronic liver diseases.
Alcoholic liver disease
Alcoholic liver disease affects several million people
worldwide and can progress from hepatic fat accumulation
(steatosis) and alcoholic steatohepatitis to cirrhosis and
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hepatocellular carcinoma [30]. Based on current under-
standing, multiple pathogenic factors are involved in the
development of alcoholic liver disease [31, 32]. Both clinical
and experimental evidence show that alcohol abuse is asso-
ciated with dysbiosis. Transfer of the dysbiotic intestinal
microbiota from alcoholic hepatitis patients to germ-free and
conventionalizedmice demonstrated that alcohol-associated
dysbiosis contributes to the development of alcoholic liver
disease [33]. In addition, gut barrier dysfunction and
increased intestinal permeability have been implicated in
alcohol-induced liver injury [34]. Mechanistically,
acetaldehyde, which is a product of ethanol metabolism, and
the generation of reactive oxygen species through cyto-
chrome P450 2E1 induction might contribute to tight junc-
tion disruption leading to increased permeability during
alcohol consumption [35]. In addition, intestinal inflamma-
tion is an importantmediator of intestinal barrier dysfunction
during alcohol consumption [11].
Bacterial translocation in alcoholic liver disease
In line with increased intestinal permeability, translocation
of bacteria has been implicated in the development of
alcoholic liver disease. Experimental induction of bacterial
overgrowth in the small intestine alone is sufficient to
result in bacterial translocation and subsequent liver dis-
ease [36]. Inversely, administration of non-absorbable
antibiotics prevented bacterial overgrowth, reduced
pathological bacterial translocation and ameliorated etha-
nol-induced steatohepatitis in rodents [37]. Moreover,
plasma levels of gut-derived microbial products such as
LPS and peptidoglycan are increased during alcohol
administration [38, 39]. Recently, our group demonstrated
that besides bacteria, also fungi contribute to alcohol-re-
lated liver disease. Increased fungal growth and translo-
cation of fungal products to the liver activate inflammatory
immune responses in the liver of ethanol-fed mice. This
process is mediated via b-glucan recognition by CLEC7A
on Kupffer cells. Moreover, relatively to healthy people,
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Fig. 1 Steatosis (fatty liver) due to obesity (diet), alcohol consump-
tion, other environmental or genetic factors is associated with
dysbiosis, loss of intestinal tight junctions, reduced intestinal
epithelial integrity, increased permeability and lower expression of
antimicrobial proteins (AMPs). This allows bacterial products such as
LPS (via the paracellular route) or viable bacteria (via not further
detailed mechanisms) to translocate into the bloodstream and
mesenteric lymph nodes. Via the portal vein, bacteria and their
products reach the liver, where they promote progression to more
severe stages of liver disease via recognition by Toll-like receptors
(TLRs) on Kupffer cells, hepatic stellate cells and hepatocytes,
leading to inflammation, fibrosis and cell death (Figure made using
Servier Medical Art; http://smart.servier.com)
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alcohol-dependent patients showed altered fungal signature
and increased exposure and immune reactivity to fungal
products in the blood, indicating fungal translocation [40].
Taken together, these data support that during alcoholic
liver disease, epithelial damage in the intestine leads to
pathological translocation of microbial products, thereby
causing liver damage.
Antimicrobial defense during alcoholic liver disease
We previously described that chronic alcohol consumption
suppresses REG3c and REG3b mRNA and protein levels
in murine small intestine [19, 21], and duodenal REG3c in
patients with alcohol use disorder [21]. In mice, the lowest
levels of Reg3c and Reg3b were observed in the proximal
small intestine, where the bacterial overgrowth was most
pronounced and luminal alcohol concentrations are highest
[21]. Decreased REG3c can be restored using prebiotics,
which are associated with suppression of intestinal bacte-
rial overgrowth. We have demonstrated that ethanol-fed
Reg3c-/- and Reg3b-/- mice have increased susceptibility
to ethanol-induced liver disease, in association with
increased mucosa-associated bacteria and more transloca-
tion of bacteria to the liver. In line, intestine-specific
overexpression of Reg3c protects mice against ethanol-in-
duced liver disease by maintaining an inner mucus layer
devoid of bacteria and reducing bacterial translocation
[12]. How a reduced number of mucosa-associated bacteria
results in lower bacterial translocation is not known. Fur-
ther, mice deficient for mucin-2 production that were
protected against alcohol-induced liver lesions showed
increased defensin production as well as that of Reg3b and
Reg3c [19]. These data indicate that antimicrobial defense
plays an important role in preventing bacterial transloca-
tion and protect against alcoholic liver disease develop-
ment. Other antimicrobial molecules do not seem to be
suppressed by chronic ethanol treatment [21], although a
global analysis using transcriptomic or proteomic approa-
ches should be done in future studies.
Recent findings from our laboratory suggest that Reg3c
and Reg3b suppression during alcoholic liver disease is an
indirect effect of alcohol consumption. Using chronic–
binge ethanol-fed mice as a model of alcoholic steato-
hepatitis [41], we found that dysbiosis upon ethanol con-
sumption is associated with altered tryptophan metabolism
by bacteria [42, unpublished data]. Ethanol feeding resul-
ted in lower levels of indole-3-acetic acid, a ligand for the
AhR [29, ], and reduced production of IL-22 by intestinal
lamina propria ILC3. Importantly, AhR-dependent pro-
duction of IL-22 regulates REG3c and REG3b expression.
Administration of non-absorbable antibiotics to ethanol-fed
mice restored IL-22 production, indicating the influence of
microbiota on regulating IL-22 expression [42,
unpublished data]. Taken together, these data suggest that
alcohol consumption changes microbial composition,
thereby affecting the bacterial metabolome which alters
host immunity and allows bacterial translocation.
Nevertheless, the exact mechanism of how chronic
ethanol administration results in changes of the luminal
intestinal microbiota composition is not fully elucidated.
Undoubtedly, chronic alcohol consumption affects multiple
factors in the host and more mechanistic studies are needed
to fully understand how changes in the gut microbiome
impact liver function during alcoholic liver disease and
vice versa.
Non-alcoholic fatty liver disease
The prevalence of NAFLD is increasing worldwide and is
considered to be a hepatic manifestation of the metabolic
syndrome. Due to its strong association with obesity and
type 2 diabetes, the pathogenesis of NAFLD and its pro-
gression to more complicated conditions have been widely
accepted to be the result of multiple factors including
intestinal dysbiosis [43, 44]. Similar to patients with
alcoholic fatty liver disease, studies show that a shift in the
gut microbiota composition correlates closely with the
prevalence and progression of NAFLD. In patients with
NAFLD, a decrease of some selected members of Firmi-
cutes has been observed and obese patients with non-al-
coholic steatohepatitis (NASH) had reduced Bacteroidetes
compared with healthy controls [45]. Severity of NAFLD
is associated with gut dysbiosis and microbial metabolome
[46, 47]. These studies indicate that an alteration in the
composition of the gut microbiota is closely associated
with the development of NAFLD.
Different microbiota-dependent mechanisms have been
suggested to contribute to NAFLD pathogenesis and pro-
gression. Ethanol-producing bacteria were proposed to be
more abundant in NASH patients [48]. Further, dysbiosis
may result in production and translocation of LPS and
other inflammatory factors, changes in bile acid metabo-
lism, and increased gut permeability in a subset of NAFLD
patients [49]. This facilitates translocation of bacterial
products into the portal circulation and activation of
inflammatory processes.
Bacterial translocation in NAFLD
Studies in rodent models have shown correlations between
hepatic inflammation and dysfunction of the intestinal
mucosal barrier, which suggest that intestinal mucosal
barrier malfunction and bacterial translocation influence
the pathogenesis of NAFLD and NASH. Indeed, it has been
shown that tight junction disruption in mice and NAFLD
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patients increases intestinal permeability and bacterial
translocation to the liver through the bloodstream [50–52].
Nevertheless, data suggest that only a portion of NAFLD
patients have increased intestinal permeability. It was
reported that serum endotoxin levels were increased in only
42.1% (8/19) patients with NASH and a meta-analysis
found that only 39.1% of patients with NAFLD (n = 128)
had increased intestinal permeability [53]. Therefore, gut
barrier dysfunction with subsequent translocation of
microbial products might make only a small contribution to
development or progression of fatty liver disease, or only in
a subset of patients.
Antimicrobial defense during NAFLD
Similar to chronic ethanol consumption, animal models of
diet-induced obesity indicate a downregulation of intestinal
Reg3c [54]. Recently, we explored the role of Reg3 lectins
in the development of NASH. To induce NASH, mice
deficient for REG3b or REG3c were fed a Western-style
fast-food diet (rich in saturated fat, cholesterol and fruc-
tose) for 20 weeks. Loss of REG3b or REG3c did not
cause more severe liver disease than in their WT litter-
mates, despite elevated endotoxemia in Reg3c-deficient
mice. In addition, intestinal overexpression of REG3c did
not protect mice against NASH development [55]. Overall,
these results indicate that loss of REG3b or REG3c is
insufficient to aggravate diet-induced obesity and NAFLD.
Vitamin D insufficiency, which has been associated with
metabolic syndrome and NAFLD, has been found to be
associated with loss of Paneth cell defensins, which may
consequently lead to intestinal dysbiosis and endotoxemia.
Moreover, oral administration of human alpha-defensin 5
rebalanced gut microbiota and resolved hepatic steatosis in
mice [56]. Further, cathelicidin, another antimicrobial
peptide, suppresses lipid accumulation and hepatic steato-
sis via the inhibition of the CD36 receptor [57]. Recently,
the expression of cathelicidin-related antimicrobial peptide
(Cramp), the only member of cathelicidin antimicrobial
peptide family in mice, was found to be decreased by
alcohol exposure to mice [58]. More studies investigating
the function of different antimicrobial proteins during fatty
liver disease development and progression are needed.
Nevertheless, current data support the notion that bacterial
translocation might not be as important during NAFLD as
observed in patients with alcohol use disorder and alcohol-
induced liver disease.
Cirrhosis
For most chronic liver diseases, cirrhosis is the common
end-stage histologic distortion, characterized by the pres-
ence of regenerative nodules that causes portal hyperten-
sion. This in turn induces bacterial overgrowth by altering
intestinal motility [59]. The gut–liver axis is well studied
during cirrhosis and complications such as hepatic
encephalopathy, spontaneous bacterial peritonitis and var-
iceal bleeding are the result of pathological translocation of
bacteria or their products into the blood of cirrhotic patients
[60–63]. Evidence from both animal and patient studies
indicates a loss of epithelial tight junctions during cirrhosis.
Patients or mouse models of liver cirrhosis showed reduced
intestinal expression of zonula occludens-1, occludin and
claudin-1 compared to controls, and these changes were
more evident in cases of decompensated or more advanced
stage of disease [64]. Moreover, intestinal permeability is
enhanced via increased production of lipid peroxidation
products such as malondialdehyde in the intestine, as
described in patients and rats with cirrhosis [65, 66].
Bacterial translocation in cirrhosis
In patients with cirrhosis, changes in gastrointestinal bar-
rier and dysbiosis increase the rate of bacterial transloca-
tion [62]. Indeed, cirrhotic patients have increased levels of
LPS and bacterial DNA in the portal circulation compared
to healthy controls, with increasing amounts as the liver
function worsens [67, 68]. Whereas the rate and degree of
translocating bacterial products are higher in early cirrhosis
compared to healthy conditions, pathological translocation
of viable bacteria occurs in the decompensated stage of the
disease. During decompensated cirrhosis, a further increase
in intestinal permeability could be triggered by intestinal
inflammation and may contribute to enhanced translocation
of viable bacteria [69, 70]. Living bacteria appear to
translocate via the transcellular route (transcytosis),
whereas microbial products migrate via disrupted tight
junctions using the paracellular route and further enhance
the local and systemic inflammatory response [71]. Positive
cultures from mesenteric lymph nodes are found in about
50–60% of rats with CCl4-induced cirrhosis and in 30% of
cirrhotic patients [72, 73], supporting that pathological
bacterial translocation plays an important role in disease
progression during cirrhosis.
Antimicrobial defense during cirrhosis
Besides intestinal immune cell damage, several studies
point to deficiencies in the production of intestinal
antimicrobial peptides during cirrhosis. Cirrhotic rats with
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ascites and translocation of viable bacteria to mesenteric
lymph nodes produce lower levels of defensins molecules
compared with cirrhotic rats without bacterial translocation
[20]. The transcription factor farnesoid X receptor (FXR),
which is the nuclear receptor for conjugated bile acids,
plays a crucial role in preserving intestinal epithelial
integrity by increasing antimicrobial peptide production
and secretion [74]. Treatment of cirrhotic rats with obeti-
cholic acid, a potent agonist of FXR, significantly reduced
bacterial translocation from the intestine to the blood via
upregulation of antimicrobial proteins angiogenin-1 and a-
5 defensin, as well as tight junction proteins, and reduced
liver fibrosis [75]. Further, liver cirrhosis in advanced
stages is frequently associated with malnutrition [76],
which has deleterious effects on gut mucosal integrity and
antimicrobial peptides [77]. Data on the expression of
intestinal AMPs in cirrhosis are scarce. Mucosal expression
of several different AMPs was not altered in the ileum or
colon of patients with cirrhosis as compared with healthy
controls [78]. Taken together, experimental data in animal
models underline the concept of intestinal antimicrobial
deficiency in cirrhosis. Measurements of AMPs in more
and larger patient cohorts should be undertaken.
Modulation of antimicrobial proteins as treatment
for liver disease
Since bacterial translocation and reduced expression of
certain antimicrobial proteins in the gut are observed in
rodents and humans with liver disease, designing a strategy
to increase intestinal concentrations of antimicrobial pro-
teins or their production by intestinal epithelial cells might
be developed to prevent liver disease.
Antibiotics
Non-absorbable antibiotics have a beneficial effect on
NASH [79] and alcoholic liver disease [37], and are
commonly used to treat patients with cirrhosis [80].
Although the use of antibiotics seems to have a beneficial
effect by reducing bacterial overgrowth and preventing
bacterial translocation, no evidence supports that this is
achieved by increased expression of antimicrobial proteins.
Nevertheless, recent data from our group indicate that non-
absorbable antibiotics can restore IL-22 production by
ILC3 s during ethanol diet [42, unpublished data]. There-
fore, changes in the microbial metabolome, the composi-
tion of microbiota, or host immunity due to antibiotics
might affect antimicrobial responses indirectly.
Probiotics and prebiotics
Probiotics regulate antimicrobial defense. For instance,
probiotic Escherichia coli Nissle 1917 and a variety of
other probiotics such as lactobacilli strongly induced the
expression of human beta-defensin-2 in epithelial cell lines
[81]. In addition, probiotic lactobacilli strains are not only
able to upregulate enterocyte human beta-defensin 2 (hBD-
2) production in vitro [82]; some species, such as Lacto-
bacillus lactis, have been demonstrated to be resistant to
the antimicrobial effects of this defensin [83]. Apart from
the induction of AMP, probiotics might affect cytokine-
producing innate cells in the mucosa (e.g., IL-22) that can
increase the expression of Reg3 lectins. As such, probiotic
Lactobacillus reuteri was found to produce AhR ligands
from tryptophan metabolism, thereby enhancing IL-22
production and mucosal defense [29]. This host–commen-
sal interplay is a prime example of how beneficial bacteria
might enhance the immune response to protect the host
from pathogens.
Prebiotics are complex short-chain saccharides that
cannot be digested by host pancreatic and brush-border
enzymes, but can be selectively used and fermented by the
commensal microbiota. They stimulate probiotic bacteria
such as lactobacilli and bifidobacteria [84]. Interestingly,
we found that decreased REG3c level during ethanol-in-
duced liver disease can be partly restored using prebiotics.
Adding fructooligosaccharides to ethanol-fed mice reduced
ethanol-induced steatohepatitis and intestinal bacterial
overgrowth by partial restoration of REG3c [21]. Current
evidence supporting a beneficial effect of prebiotics for
NAFLD and cirrhosis is lacking. More studies and larger
clinical trials are needed to support the use of pre- and
probiotics in different chronic liver diseases.
Conclusion
In conclusion, several human and mouse studies have
demonstrated that intestinal barrier dysfunction, bacterial
translocation and a deficiency in various antimicrobial
proteins are implicated in the development of chronic liver
disease. We are gaining increased insight into the close
relationship between the gut and the liver evoked by dys-
biosis. The evaluation of the gut–liver axis and the inter-
vention of the relationships between antimicrobial peptides
and bacteria might aid the development of treatment and
prevention for liver disease patients. Finally, besides bac-
teria, the intestinal microbiota also includes eukaryotic
viruses [85], bacteriophages [86], and eukaryotic organ-
isms such as fungi [87]. However, studies were mainly
focused on the interaction between AMPs and bacteria.
Therefore, studies to explore the influence of AMPs on
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other microbial communities will be interesting. In that
way, more insights in the communication between host and
microbiome will be made which may provide new strate-
gies for improving health and disease management.
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